Jump to content
Powered by

Dossiers

Here you can find dossiers on topics related to the healthcare industry. New articles about state-of-the-art knowledge will always be posted in the overview articles section.

  • Dossier - 30/05/2011

    Technology transfer that efficiently exploits the intellectual property created by publicly funded research is necessary in order to turn scientific discoveries into successful innovations that improve people’s quality of life and boost the economy. The efforts made to rapidly transfer research results from the laboratory into clinical application for the benefit of patients leads to new strategic partnerships and structures in the field of…

  • Dossier - 02/05/2011

    Knowledge about the molecular organisation of structural and functional biological properties has led to the establishment of a new field of research molecular bionics. Everything that can be learnt from the macromolecular observation of interesting natural phenomena is complemented in this field by observations on the smallest i.e. molecular level. Processes and materials that have been optimised in the course of evolution are thus able to…

  • Dossier - 28/02/2011

    According to the Federal Health Monitoring Information System a persons life expectancy is reduced by around one per cent due to allergies and their effects. Knowledge about the molecular mechanisms that lead to disorders in the interplay of the immune system and the environment is a prerequisite for developing new therapies for the causal treatment of allergies.

  • Dossier - 07/02/2011

    A promising future does not easily disappear into thin air. This is certainly the case with the vision of personalised medicine. For many years, biomedical researchers have vaunted the potential benefits of their findings despite the fact that neutral observers do not think that personalised medicine will really take off within the next 15 or 20 years. Moreover personalised medicine is a controversial term. So what is the state of play right now?

  • Dossier - 20/12/2010

    Environmental toxins, also referred to as xenobiotics, are chemicals that do not occur in biological substance cycles; they are difficult to degrade and often have a toxic effect. Xenobiotic substances are becoming an increasing problem because we are constantly exposed to them and because they slowly but surely poison us. The World Health Organisation (WHO) sees xenobiotic substances as factors that contribute, along with other factors, to the…

  • Dossier - 29/11/2010

    Everybody wants safe drugs – manufacturers, doctors and patients. However, many dangers, both avoidable and unavoidable, make medicinal treatment a high-risk process, despite all best efforts and assertions. Not enough information on drug-related risks is available, and the estimated number of adverse drug reactions that go unreported is quite high.

  • Dossier - 15/11/2010

    Evidence-based medicine revolves around the principle that doctors only use medications and therapies whose efficacy and usefulness has been reliably proven in scientific studies. The idea behind evidence-based medicine is to improve the quality of medical treatment as well as enable the more rational usage of limited resources in the healthcare sector. However many critics believe that evidence-based medicine has methodological limits in…

  • Dossier - 18/10/2010

    Hardware and software applications have become an integral part of the everyday life of life sciences researchers, developers and service providers. It is impossible to imagine life science applications without effective hardware and software applications – from computer-assisted drug screening to the automatic production of biosensors for rapid, mobile, purse-size bacterial test devices. Trends such as automation and miniaturisation lead to ever…

  • Dossier - 20/09/2010

    It is estimated that around 1.2 million people in Germany suffer from dementia, and around 200,000 people are diagnosed with neurodegenerative diseases every year. It is expected that by 2050, one in three people in Germany will be over 60 and the number of age-related diseases, particularly dementias, for which no effective curative therapy is currently available, will increase considerably. Given the large numbers of elderly people and…

  • Dossier - 30/08/2010

    “Classical treatment approaches are not the only way to ensure good health, rehabilitation and care. In fact, it is envisaged that more effective prevention will contribute to halting the development of diseases and maintaining good health. Prevention is designed to prevent health risks and diseases, make them less likely and delay their onset.” (Declaration of the German government; Official Records of Parliament 17/845, 26th February 2010)

  • Dossier - 09/08/2010

    Biomolecules such as peptides and nucleic acids can nowadays be synthesised relatively quickly and inexpensively. In addition, great progress has been made in the development of methods enabling the directed mutagenesis in microorganisms. These two developments have boosted the design of new, and the reorganisation of known, molecules. Moreover, these help in the utilisation of certain molecule functions in research and in the industrial…

  • Dossier - 10/07/2010

    Around thirty per cent of all cellular proteins are located in or on a biological membrane. Numerous diseases are associated with defects in these proteins. It is estimated that around 50 per cent of all drugs developed by the pharmaceutical industry in the future will target the different membranes of cells. However it is quite difficult to biochemically investigate biological membranes. These are the many reasons why many research groups and…

Website address: https://www.gesundheitsindustrie-bw.de/en/article/dossier